Thursday, May 26, 2016 7:09:44 PM
By MICHAEL NEDELMAN May 26, 2016, 6:25 PM ET
Click For Additional ABC News
Braeburn Pharmaceuticals-A newly FDA-approved implant, Probuphine, releases a low dose of medication to treat opioid addiction.
The first implantable treatment for opioid addiction was approved today by the U.S. Food and Drug Administration.
The implant, a match-sized rod that is inserted under the skin, releases a milder opioid drug called buprenorphine that is usually taken orally to treat addiction. Under the name Probuphine, the implant comprises four rods that release the drug at a low dose for six months.
“Anyone who’s gone through addiction knows that motivation fluctuates day to day. This allows a person to decide for their future self,” Dr. Keith Humphreys, a Stanford psychiatrist who also served as a senior policy advisor at the White House Office of National Drug Control Policy, told ABC News.
The implant is designed for opioid addicts who are “already stable on low-to-moderate doses” of oral buprenorphine, the FDA said in a statement. Experts like Humphreys believe this could be a game-changer for the 2.5 million Americans with an opioid addiction.
Experts also say that an implantable rod could prevent addicts from abusing the oral drug.
In January, an FDA advisory committee voted 12-to-5 to recommend the implant for FDA approval, but it was unclear how the FDA would act on that recommendation until today.
While Probuphine was found to be about as effective as the oral medication, the FDA advisory report raised the question of who would be implanting and removing the rods. Relatively few buprenorphine prescriptions are written by doctors with surgical training, the report said.
“A typical psychiatrist hasn’t laid their hand on a patient in 20 years,” Humphreys said.
Early tests showed that even clinicians who regularly performed procedures were unable to remove the implant in some cases, according to the report.
“There have been improvements in the tools and techniques,” said Behshad Sheldon, CEO of Braeburn Pharmaceuticals, which markets Probuphine with San Francisco–based Titan Pharmaceuticals.
Both the implantation and removal kits have undergone recent changes to make it easier for doctors and reduce bruising, Sheldon told ABC News.
While side effects have been rarely reported in clinical trials, they may typically include infection at the injection side, according to the FDA report.
Braeburn aims to make the product widely available to patients starting June 21, said Sheldon, adding that it will cost “under $1,000 a month” but declining to provide an exact price.
But Sarah Wilson, a mother of four who was involved in the implant trials, said she has already seen some benefit.
Wilson told ABC News that she became addicted to hydrocodone seven years ago after being hit by a drunk driver and developing chronic pain. She began taking oral buprenorphine to get sober and was later transitioned to the Probuphine implant.
She said she stopped worrying that her kids would get into her medication or that her local pharmacy would not have the drug in stock. She also stopped waking up in the early morning when she felt the oral drugs would wear off, she said.
“I went from existing to living,” Wilson said.
ABC News’ Dr. Sunjay Devarajan contributed to this report.
Blessings to All
TRUTH
I've never claimed to have all the answers but feel i'm beginning to corner the market in questions worthy of them.
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:03:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:33:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:25:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:23:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/24/2023 09:26:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 07:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2023 09:08:35 PM
- Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors • GlobeNewswire Inc. • 10/16/2023 08:37:23 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/04/2023 09:30:18 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:41:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 08:45:22 PM
- Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock • GlobeNewswire Inc. • 09/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:30:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:28:25 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM